WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1998031369) EXTERNAL PREPARATIONS FOR PERCUTANEOUS ABSORPTION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1998/031369    International Application No.:    PCT/JP1998/000123
Publication Date: 23.07.1998 International Filing Date: 16.01.1998
Chapter 2 Demand Filed:    12.06.1998    
IPC:
A61K 9/06 (2006.01), A61K 9/70 (2006.01), A61K 31/519 (2006.01)
Applicants: SEKISUI CHEMICAL CO., LTD. [JP/JP]; 4-4, Nishitenma 2-chome Kita-ku Osaka-shi Osaka 530 (JP) (For All Designated States Except US).
ITO, Kazushi [JP/JP]; (JP) (For US Only).
KAWAMORI, Tadao [JP/JP]; (JP) (For US Only).
MATSUDA, Masanori [JP/JP]; (JP) (For US Only).
KURIYAMA, Kiyoshi [JP/JP]; (JP) (For US Only)
Inventors: ITO, Kazushi; (JP).
KAWAMORI, Tadao; (JP).
MATSUDA, Masanori; (JP).
KURIYAMA, Kiyoshi; (JP)
Agent: YASUTOMI, Yasuo; Recruit Shin Osaka Building, 4F 14-22, Nishinakajima 5-chome Yodogawa-ku, Osaka-shi Osaka 532 (JP)
Priority Data:
9/5516 16.01.1997 JP
9/72294 25.03.1997 JP
9/347999 17.12.1997 JP
Title (EN) EXTERNAL PREPARATIONS FOR PERCUTANEOUS ABSORPTION
(FR) PREPARATIONS A USAGE EXTERNE A ABSORPTION PERCUTANEE
Abstract: front page image
(EN)External preparations of methotrexate for percutaneous absorption, having systemic therapeutic effects on, for example, chronic inflammatory diseases such as autoimmune diseases (rheumatoid arthritis, etc.) and cancerous diseases such as leukemia and aiming at relieving the side effects of methotrexate and improving the compliance and quality of life of patients. These preparations contain a chemical (i.e., methotrexate) in the bases and exert systemic therapeutic effects on the patients.
(FR)L'invention porte sur des préparations de méthotréxate à absorption percutanée dotées d'effets thérapeutiques systémiques sur des maladies inflammatoires chroniques telles que les maladies auto-immunes (polyarthrite rhumatoïde, etc.) et les cancers tels que la leucémie, et tendant à soulager les effets secondaires du méthotréxate, et à améliorer l'observance et la qualité de vie des patients. Lesdites préparations, qui contiennent du méthotréxate dans leurs bases, exercent des effets thérapeutiques systémiques sur les patients.
Designated States: AU, CA, CN, JP, KR, RU, US.
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)